Lutathera clinical trials
Lutathera is named as an intervention in 11 current clinical trials in our France, Spain, USA, UK, Canada, Germany, South Korea, Portugal, Austria, Switzerland, Italy, Netherlands, Poland, China, Czechia, Singapore, Israel, Norway and Mexico registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Advanced Accelerator Applications (3). The most-studied condition is Neuroendocrine Tumors.
Patient leaflets for Lutathera
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Lutathera
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Lutathera
22 conditionsAll 22 conditions
| Condition (as registered) | Trials |
|---|---|
| Neuroendocrine Tumors | 3 |
| Gastro-enteropancreatic Neuroendocrine Tumor | 1 |
| Gastroenteropancreatic Neuroendocrine Tumors | 1 |
| Pheochromocytoma | 1 |
| Paraganglioma | 1 |
| Extensive Stage Small Cell Lung Cancer | 1 |
| Glioblastoma | 1 |
| Recurrent Meningioma | 1 |
| Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | 1 |
| Intestinal Well Differentiated Endocrine Tumor | 1 |
| Progressive Disease | 1 |
| Intestinal Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Metastatic Digestive System Neuroendocrine Tumor G1 | 1 |
| Metastatic Digestive System Neuroendocrine Tumor G2 | 1 |
| Unresectable Digestive System Neuroendocrine Tumor G1 | 1 |
| Unresectable Digestive System Neuroendocrine Tumor G2 | 1 |
| Metastatic Pancreatic Neuroendocrine Tumor | 1 |
| Pancreatic Neoplasm | 1 |
| Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
| Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Advanced Accelerator Applications | 3 |
| Novartis Pharmaceuticals | 2 |
| National Cancer Institute (NCI) | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Grupo Espanol de Tumores Neuroendocrinos | 1 |
| Institut du Cancer de Montpellier - Val d'Aurelle | 1 |
| Sociedad Española de Medicina Nuclear e Imagen Molecular | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Lutathera trials
How many clinical trials are testing Lutathera?
11 current trials in our France, Spain, USA, UK, Canada, Germany, South Korea, Portugal, Austria, Switzerland, Italy, Netherlands, Poland, China, Czechia, Singapore, Israel, Norway and Mexico registers name Lutathera (also registered as AAA601) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Lutathera trials recruiting patients?
Yes. 6 of the 11 trials are recruiting: 3 with sites in France, 3 with sites in Spain, 2 with sites in Canada, 1 with sites in Germany, 1 with sites in Austria, 1 with sites in Switzerland, 1 with sites in Norway and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Lutathera clinical trials?
Advanced Accelerator Applications (3), Novartis Pharmaceuticals (2), National Cancer Institute (NCI) (2) and European Organisation for Research and Treatment of Cancer - EORTC (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lutathera works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lutathera works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lutathera (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.